Neuphoria Therapeutics Inc.
NEUP Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$3.44
KIRA · Stoqly’s AI analyst, in plain words
- Neuphoria Therapeutics Inc. had $1.2M of revenue in fiscal 2026, down 92.5% on the year before.
- Its operating margin was −1,401.0%, down 1,393.8 pts: of every 100 in sales, about −1,401 is left after running the business.
- Neuphoria Therapeutics Inc. lost $13.5M in fiscal 2026.
Market cap
$15.1M
P/E
—
Revenue
$1.2M
Net income
−$13.5M
Free cash flow
—
Operating margin
−1,401.0%
Neuphoria Therapeutics Inc. in 30 seconds · fiscal 2026
Are sales growing?
−92.5%
No. Sales fell 92.5% last year.
Does it make a profit?
−1,145.6%
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Neuphoria Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Sep 18, 2026
- Legal name
- Neuphoria Therapeutics Inc.
- CIK
- 0001191070
Neuphoria Therapeutics Inc. · NEUP
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | — | — | $15.6M | $1.2M |
| Revenue growth | — | — | — | −92.5% |
| Operating margin | — | — | −7.2% | −1,401.0% |
| Net income | −$21.4M | −$15.5M | −$0.4M | −$13.5M |
| Net margin | — | — | −2.4% | −1,145.6% |
| Diluted EPS | −$0.02 | −$18.62 | −$0.23 | −$3.06 |
| Cash | ||||
| Cash from operations | −$14.6M | −$14.7M | $0.1M | −$12.4M |
| Share count change | — | −99.9% | 95.0% | 170.9% |
| Debt and strength | ||||
| Cash and short-term investments | $12.1M | $12.6M | $14.2M | $19.9M |
| Shareholders' equity | $22.0M | $17.5M | $19.0M | $24.6M |
| Current ratio | 4.9x | 3.4x | 3.6x | 27.8x |
| Returns and quality | ||||
| Return on equity | −97.1% | −78.4% | −2.0% | −61.7% |
| Return on tangible equity | −297.5% | −464.8% | −6.6% | −79.3% |
| Piotroski F-score | — | — | — | 2 |
| Altman Z'' | −17.8 | −21.3 | −16.0 | −14.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Neuphoria Therapeutics Inc. · NEUP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.44 a share, the company is worth $15.1M.
Source: SEC EDGAR XBRL filings (CIK 0001191070). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.